Skip to main content
Log in

A study of a different dose-intense infusion schedule of phenylacetate in patients with recurrent primary brain tumors

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

Purpose: To compare two different infusion schedules of phenylacetate (PA) in patients with primary brain tumors and to assess the feasibility of the administration in a multi-institutional setting. Patients and methods: Adult patients with recurrent primary brain tumors were treated with PA on two different schedules. The first schedule (I) consisted of a 2-week continuous, intravenous infusion followed by a 2-week rest period (14 days on, 14 days off) at a dose of 400 mg/kg/day based on ideal body weight. This was repeated once and the 8-week period defined as a cycle. The second schedule (II) consisted of a 12-day continuous infusion at a dose of 400 mg/kg/day based on IBW with a 2-day rest period. This was repeated four times for a duration of 8 weeks which defined one cycle of therapy. Cycles were repeated until tumor progression, unacceptable toxicity, or a delay of more than 28 days from the last day of the preceding infusion. Tumor response was assessed every 8 weeks. The National Cancer Institute toxicity criteria were used to assess toxicity. Dose adjustments were specified for toxicities. Plasma concentrations achieved during the patients' first cycle of therapy were assessed. Results: The clinical results of the phase II study of patients treated on schedule I were previously reported [8]. Of the nine eligible patients treated on schedule II, seven were assessable for radiographic response. There were no objective responses. One patient had stable disease and six had progressive disease. The median survival was 9 months (95% confidence intervals of 3–12 months). The steady state plasma concentrations of PA and phenylacetylglutamine were comparatively the same between the two dosing schedules. However a 1.7-fold greater amount of PA was delivered by schedule II. Conclusion: The infusions were well tolerated. Despite the feasibility of administering this agent in an outpatient setting, there were no responses seen with the more intensive schedule of PA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Brusilow SW, Danney M, Waber LJ, Batshaw M, Burton B, Levitsky L, Roth K, McKeethren C, Ward J: Treatment of episodic hyperammonemia in children with inborn errors of urea synthesis. N Engl J Med 310: 1630–1634, 1984

    Google Scholar 

  2. Simell O, Sipila I, Rajantie J, Valle DL, Brusilow SW: Waste nitrogen excretion via amino acid acylation: benzoate and phenylacetate in lysinuric protein intolerance. Pediatr Res 20: 1117–1121, 1986

    Google Scholar 

  3. Watson AJ, Karp JE, Walker WG, Chambers T, Risch VR, Brusilow SW: Transient idiopathic hyperammonaemia in adults. Lancet 2: 1271–1274, 1985

    Google Scholar 

  4. Hudgins WR, Skack S, Myers CE, Samid D: Cytostatic activity of phenylacetate and derivatives against tumor cells. Biochem Pharmacol 50: 1273–1279, 1995

    Google Scholar 

  5. Schmidt F, Groscurth P, Kermer M, Dichgans J, Weller M: Lovastatin and phenylacetate induce apoptosis, but not differentiation, in human malignant glioma cells. Acta Neuropathol 101: 217–224, 2001

    Google Scholar 

  6. Pineau T, Hudgins W, Liu L, Chen L, Sher T, Gonzalez F, Samid D: Activation of a human peroxisome proliferator-activated receptor by the antitumor agent phenylacetate and its analogs. Biochem Pharmacol 52: 659–667, 1996

    Google Scholar 

  7. Ram Z, Samid D, Walbridge S, Oshiro E, Viola J, Tao-Cheng J, Shack S, Thibault A, Myers C, Oldfield E: Growth inhibition, tumor maturation, and extended survival in experimental brain tumors in rats treated with phenylacetate. Cancer Res 54: 2934–2927, 1994

    Google Scholar 

  8. Chang S, Kuhn J, Robins I, Schold SC, Spence AM, Berger MS, Mehta MP, Bozik ME, Pollack I, Schiff D, Gilbert M, Rankin C, Prados M: Phase II study of Phenylacetate in patients with recurrent malignant glioma: A North American brain tumor consortium. J Clin Onc 17: 984–990, 1999

    Google Scholar 

  9. Thibault A, Cooper MR, Figg WD, Venzon DJ, Sartor AO, Tompkins AC, Weinberger MS, Headlee DJ, McCall NA, Samid D, Myers CE: A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. Cancer Res 54: 1690–1694, 1994

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Susan M. Chang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chang, S.M., Kuhn, J.G., Ian Robins, H. et al. A study of a different dose-intense infusion schedule of phenylacetate in patients with recurrent primary brain tumors. Invest New Drugs 21, 429–433 (2003). https://doi.org/10.1023/A:1026299118067

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1026299118067

Navigation